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Abstract Aim: The optimal second-line regimen for treating advanced gastric cancer (AGC)
remains unclear. While irinotecan (CPT-11) plus cisplatin (CDDP) combination therapy and
CPT-11 monotherapy have been explored in the second-line setting, the superiority of second-
line platinum-based therapies for AGC patients initially treated with S-1 monotherapy has not
yet been evaluated; therefore, we aimed to examine the survival beneﬁt of CPT-11/CDDP
combination over CPT-11 monotherapy.
Methods: AGC patients showing progression after S-1 monotherapy for advanced cancer or
recurrence within 6 months after completion of S-1 adjuvant therapy were randomly allocated
to CPT-11/CDDP (CPT-11, 60 mg/m2; CDDP, 30 mg/m2, q2w) or CPT-11 (150 mg/m2, q2w).
Results: Sixty-eight advanced and 95 recurrent cases were evaluated. The median overall sur-
vivals were 13.9 (95% conﬁdence interval [CI]: 10.8–17.6) and 12.7 (95% CI: 10.3–17.2) months
for CPT-11/CDDP and CPT-11, respectively (hazard ratio: 0.834; 95% CI: 0.596–1.167,
P = 0.288). No signiﬁcant differences were observed in the secondary end-points, including
progression-free survival (4.6 [95% CI: 3.4–5.9] versus 4.1 [95% CI: 3.3–4.9] months) and
response rate (16.9% [95% CI: 8.8–28.3] versus 15.4% [95% CI: 7.6–26.5]). The incidences of
grade 3–4 anaemia (16% versus 4%) and elevated serum lactate dehydrogenase levels (5% ver-
sus 0%) were higher for CPT-11/CDDP than for CPT-11. Exploratory subgroup analysis
revealed that CPT-11/CDDP was signiﬁcantly more effective for intestinal-type AGC, com-
pared with CPT-11 (overall survival: 15.8 versus 14.0 months; P = 0.019).
Conclusion: No survival beneﬁt was observed upon adding CDDP to CPT-11 after S-1
monotherapy failure.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Gastric cancer is the third leading cause of cancer
death worldwide [1]. Nearly 50% of patients with locally
advanced-stage gastric cancer relapse after gastrectomy,
resulting in an unfavourable long-term prognosis [2].
The survival of these patients has been demonstrated
to be markedly improved upon introduction of
postoperative adjuvant chemotherapy with S-1
monotherapy [3]. However, a number of patients
develop early recurrence after completion of adjuvant
therapy with S-1.
On the other hand, combination therapies with ﬂuo-
ropyrimidines andplatinumhave been recognised as stan-
dard regimens for the ﬁrst-line treatment of advanced
gastric cancer (AGC) [4]. In addition, EOX (epirubicin,
oxaliplatin and capecitabine) has also become a standard
regimen in Europe [5], and DCF (cisplatin [CDDP], 5-
ﬂuorouracil and docetaxel) has been developed in the
US, although its application is limited because of high
toxicity [6]. In contrast, when this study started, S-1
monotherapy was widely used as a standard regimen in
Japan [7]. Although the result of the JCOG 9912 trial
showed that S-1 monotherapy was tentatively recognised
as a standard treatment, the result of the SPIRTS trial
proved the superiority of S-1 plus CDDP combination
therapy over S-1 monotherapy [8]. However, the S-1
monotherapy regimen showed good overall survival
(OS) in both trials (11.4 and 11.0 months, respectively),
and owing to itsmodest toxicity and the fact that intensive
hydration is not required, S-1 monotherapy remains an
option for frail or unﬁt patients in Japan.
It is common practice to oﬀer further chemotherapy
for patients with AGC after failure of ﬁrst-line
chemotherapies [9]. However, currently, no established
second-line chemotherapy (SLC) regimen is available
for AGC patients. When we designed this trial, irinote-
can (CPT-11) plus CDDP combination therapy or CPT-
11 monotherapy were commonly used to treat AGC in
the second-line setting in Asia [10–13]. In a previous
phase II study using CPT-11 monotherapy as SLC,
CPT-11 was found to frequently cause diarrhoea and
febrile neutropenia [10]; therefore, CPT-11/CDDP com-
bination therapy was developed to reduce CPT-11-as-
sociated diarrhoea and febrile neutropenia by
decreasing the dose of CPT-11 [12,13]. Moreover, a
phase I/II study of bi-weekly CPT-11/CDDP com-
bination therapy showed promising eﬃcacy and a man-
ageable toxicity proﬁle [13].
However, the eﬀects of platinum-based therapies in
the second-line setting for AGC patients initially treated
by S-1 monotherapy have not yet been examined; there-
fore, this trial was designed to compare the eﬀects of
combination therapy with CPT-11 and CDDP to
CPT-11 monotherapy in patients who showed progres-
sion after at least one cycle of S-1 monotherapy for
advanced cancer or recurrence within 6 months after
completion of adjuvant therapy with S-1.
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2. Patients and methods
2.1. Patients
Patients agedP20 years were eligible for inclusion in
this multicentre, open-label, randomised phase III gas-
tric cancer chemotherapy trial in a second line setting.
Patients with histologically conﬁrmed AGC that were
refractory to the ﬁrst-line S-1 monotherapy. Tumour
progression after at least one cycle of S-1 monotherapy
for an advanced cancer, or recurrence within 6 months
after the completion of adjuvant therapy with S-1 were
considered eligible for the study. Patients who have dis-
continued S-1 monotherapy due to the adverse events
were excluded from this study. Adequate organ function
and an Eastern Cooperative Oncology Group perfor-
mance status (PS) of 0 or 1 were conﬁrmed by respective
laboratory tests (white blood cell count P4000/mm3
and 612,000/mm3, neutrophil countP2000/mm3, plate-
let countP100,000/mm3, haemoglobin levelP8.0 g/dL,
aspartate aminotransferase and alanine aminotrans-
ferase (ALT) levels 6100 IU/L, total bilirubin level
61.50 mg/dL, and creatinine level 61.20 mg/dL) and
physical examinations. Exclusion criteria included a PS
P2, history of anti-tumour therapy (except for S-1
monotherapy and surgery), additional malignancies or
signiﬁcant comorbidities. A treatment-free interval of
at least 2 weeks after S-1 monotherapy and 4 weeks after
surgery was required to be eligible for the trial.
The trial was conducted in accordance with the
Declaration of Helsinki and registered with UMIN-
CTR, UMIN 000002571. All patients provided written
informed consent after having been informed about the
purpose and investigational nature of the study. The insti-
tutional review boards or ethics committees of all partici-
pating centres reviewed and approved the protocol.
The participating investigators were instructed to send
an eligibility criteria report to the data centre, operated by
the non-proﬁt organisation Epidemiological & Clinical
Research Information Network (ECRIN). Eligible
patients were registered and subsequently Randomised
using a centralised dynamic randomisation method with
the following balancing factors: PS (0/1); disease type
(patients with progressive disease/patients with recur-
rence); measurable disease according to the criteria set
by Response Evaluation Criteria in Solid Tumours
(RECIST 1.0) (yes/no), and institution. The accrual
started in July 2007 and was continued for 4 years.
2.2. Projected treatment
Patients in the CPT-11/CDDP arm received intra-
venous CPT-11 (60 mg/m2) and CDDP (30 mg/m2) on
day 1 and every 2 weeks thereafter. Patients in the
CPT-11 arm received intravenous CPT-11 (150 mg/m2)
on day 1 and every 2 weeks thereafter. The pre-speciﬁed
regimens were discontinued if any of the following was
observed: (i) disease progression or occurrence of new
disease; (ii) grade 4 non-haematological toxicities evalu-
ated according to the Common Terminology Criteria for
Adverse Events, version 3.0; (iii) adverse events causing
patients to refuse treatment or causing a clinician to dis-
continue treatment; (iv) increase in the levels of tumour
markers in two or more consecutive measurements; or
(v) symptomatic progression.
2.3. Follow-up
Disease progression and occurrence of new disease
were examined using chest radiography and computed
tomography (CT). These were performed at baseline
and at least every 4–6 weeks during treatment, according
to the RECIST version 1.0. Blood tests and symptom
checks were performed at least every 2 weeks during
treatment.
2.4. Study design and statistical methods
The primary end-point of this study was overall sur-
vival (OS), which was deﬁned as the time from the date
of random assignment to the date of death as a result of
any cause. OS, progression-free survival (PFS) and time
to treatment failure (TTF) curves were constructed as
time-to-event plots using the Kaplan–Meier method.
Time-to-event curves were compared using log-rank
tests and hazard ratio (HR) estimated by Cox regression
models. The eﬃcacy analysis was performed using
intent-to-treat populations, wherein all randomly
assigned patients were included. It was assumed that
the OS would be 5 months in the CPT-11 arm and
8 months in the CPT-11/CDDP arm. The power of the
test was estimated as 80% with a two-sided a value of
0.05, which indicated a sample size of 80 subjects in each
arm (a total of 160 subjects). When ineligible patients or
dropouts were included, the initial target sample size
was estimated to be 200. All clinical data were held cen-
trally at the ECRIN data centre and analysed using SAS
for Windows version 9.3 (SAS Institute Inc., Cary, NC,
United States of America (USA)).
3. Results
3.1. Patient characteristics
In total, 168 patients were enrolled from 30 institutes
in Japan between July 2007 and December 2011. This
study was ended when the pre-determined number of
enrolled subjects was obtained. The numbers of patients
in the CPT-11/CDDP and CPT-11 arm were 84 and 84,
respectively. Three cases in the CPT-11/CDDP arm and
two cases in the CPT-11 arm refused to undergo treat-
ment before the start of the assigned treatment.
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Therefore, 82 and 81 patients in the CPT-11/CDDP and
CPT-11 arm, respectively, were considered eligible for
evaluation (Fig. 1). The initial patient characteristics
between the two arms were well matched (Table 1),
and the median follow-up duration was 59.0 months.
3.2. Survival
A total of 69 patients (82%) in the CPT-11/CDDP
arm and 70 patients (83%) in the CPT-11 arm had died
at the end of the study. In the intention-to-treat survival
analysis, the median OS was 13.9 (95% conﬁdence inter-
val [CI]: 10.8–17.6) months in the CPT-11/CDDP arm
and 12.7 (95% CI: 10.3–17.2) months in the CPT-11
arm. Thus, CPT-11/CDDP combination therapy did
not signiﬁcantly reduce the risk of death compared with
CPT-11 monotherapy (hazard ratio [HR]: 0.834; 95%
CI: 0.596–1.167, P = 0.288; Fig. 2A).
Similarly, no diﬀerence was observed in the median
PFS (4.6 months versus 4.1 months, respectively; HR:
0.860; 95% CI: 0.610–1.203, P = 0.376; Fig. 2B) and
the median TTF (3.3 months versus 3.5 months; HR:
1.009; 95% CI: 0.740–1.375, P = 0.956) between the
CPT-11/CDDP and CPT-11 arms.
Exploratory subgroup analysis revealed that CPT-11/
CDDP combination therapy was associated with signiﬁ-
cantly better OS in intestinal-type gastric adenocar-
cinomas compared to CPT-11 monotherapy (median
OS: 15.8 months versus 14.0 months; HR: 0.569; 95%
CI: 0.352–0.918, P = 0.019; Fig. 3). CPT-11/CDDP
combination therapy was not associated with any other
factors, including age, gender, disease status, PS, pri-
mary site, histology, peritoneal metastasis, liver metasta-
sis, target lesion and number of metastases.
3.3. Response rates
Of the 82 patients treated with CPT-11/CDDP com-
bination therapy (65 patients had measurable disease),
three achieved complete response (CR), eight achieved
Table 1
Patient characteristics.
CPT-11 + CDDP (n = 84) CPT-11 (n = 84)
Age (years)
Median 67 68
Range 36–85 35–87
Gender
Male 68 (81%) 63 (75%)
Female 16 (19%) 21 (25%)
ECOG PS
0 68 (81%) 68 (81%)
1 16 (19%) 16 (19%)
Disease type
PD 36 (43%) 35 (42%)
Recurrence 48 (57%) 49 (58%)
Measurable lesion
Yes 66 (79%) 70 (83%)
No 18 (21%) 14 (17%)
Number of metastatic sites
0 18 (21%) 13 (15%)
1 48 (57%) 53 (63%)
P2 18 (21%) 18 (21%)
Primary site
Yes 19 (23%) 10 (12%)
No 65 (77%) 74 (88%)
Histological type
Intestinal 46 (55%) 38 (45%)
Diﬀuse 38 (45%) 46 (55%)
Fig. 1. CONSORT diagram.
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partial response (PR) and 34 achieved stable disease
(SD). Of the 81 patients received CPT-11 monotherapy
(65 patients had measurable disease), one patient
achieved CR, nine achieved PR and 32 achieved SD.
The overall response rate was 16.9% (95% CI: 8.8–
28.3) and 15.4% (95% CI: 7.6–26.5), respectively
(Table 2). No signiﬁcant diﬀerence was observed
between the arms (P = 0.812).
3.4. Toxicity
All patients could be assessed for haematological and
non-haematological toxicities. Proportions of patients
who had presented any types of toxicity are shown in
Table 3. Compared to the CPT-11 arm, the CPT-11/
CDDP arm showed signiﬁcantly higher grade 3–4 toxi-
cities, regarding anaemia (16% versus 4%) and lactate
dehydrogenase level (5% versus 0%). With regard to
the incidence of any grade of adverse events, leucopenia,
thrombocytopenia and increase of serum creatinine were
more frequently observed in the CPT-11/CDDP arm,
whereas diarrhoea, constipation and mucositis were
more commonly noted in the CPT-11 arm. There were
no deaths resulting from toxicities.
3.5. Compliance
The median number of courses was ﬁve (range, 1–31)
in the CPT-11/CDDP arm and 6 (range, 1–39) in the
CPT-11 arm, respectively. Treatment delays were more
frequently observed in the CPT-11/CDDP arm (61%
versus 44%; P = 0.035). The most common reasons for
discontinuation in the CPT-11/CDDP and CPT-11 arms
were disease progression (59% and 74%, respectively)
and adverse events (28% and 11%, respectively).
However, this was not statistically signiﬁcant. A greater
number of patients in the CPT-11/CDDP arm were
unable to start new cycles within 4 weeks from the last
administration because of toxicities, compared to the
CPT-11 arm.
3.6. Post-protocol therapy
Post-protocol therapy was administered in 71% (58/
81) and 68% (55/81) of patients in the CPT-11/CDDP
and CPT-11 arms, respectively. We could not ﬁnd any
signiﬁcant diﬀerence in the regimens selected as post-
protocol therapy between the arms. Among the 55
patients in the CPT-11 arm, 46 patients did not receive
Fig. 2. Overall survival (A) and progression-free survival (B) in the intent-to-population.
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CDDP-based therapy throughout chemotherapy from
ﬁrst-line to salvage therapy.
4. Discussion
Our study did not show that CPT-11/CDDP com-
bination therapy was superior to CPT-11 monotherapy
in platinum-naı¨ve patients with progressive AGC pre-
viously treated with S-1 monotherapy (HR: 0.834; 95%
CI: 0.596–1.167; P = 0.288). The hypothesised survivals
in the statistical calculation of the protocol (estimated
median survival time: 8 versus 5 months) were much
shorter than those obtained in the trial (observed med-
ian survival 13.9 versus 12.7 months). These diﬀerences
Fig. 3. Forest plot of overall survival.
Table 2
Response rates.
CPT-11 + CDDP (n = 65) CPT-11 (n = 65) P-value
n % n %
Complete response 3 5 1 2
Partial response 8 12 9 14
Stable disease 34 52 32 49
Progressive disease 14 22 19 29
Not evaluable 6 9 6 9
Overall response rate (95% conﬁdence interval (CI)) 16.9% (8.8–28.3) 15.4% (7.6–26.5) P = 0.812
Disease control rate (95%CI) 69.2% (56.6–80.1) 64.6% (51.8–76.1) P = 0.576
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may have inﬂuenced the power of this trial, making it
underpowered to observe real diﬀerences in overall sur-
vival. If it was assumed that the OS would be
12.7 months in the CPT-11 arm, 1040 patients would
be needed to detect a survival beneﬁt of 3 months in
OS in the CPT/CDDP arm with a power of 80%.
The favourable long-term survivals observed in this
trial may be due to the good prognostic characteristics
of the patients, as only patients with PS 0–1 were consid-
ered. Moreover, the median number of metastatic sites
was only 1, and only 21% of patients had 2 or more
metastatic sites. As a result, a high proportion of the
patients (69%) who progressed after the allocated treat-
ments had received further treatment in this study.
Further, patients in this trial did not receive platinum-
based ﬁrst-line chemotherapy, which permitted a longer
duration of SLC, and the enrolment rate of recurrent
cases within 6 months after S-1 adjuvant chemotherapy
was high (58%, 97/168).
While the present study was ongoing, three trials
demonstrated a prolongation of survival with SLC
(CPT-11 or docetaxel monotherapy) over best support-
ive care [14–16], and a meta-analysis of these trials sup-
ported the eﬃcacy of SLC in the treatment of AGC [17].
In this meta-analysis, a signiﬁcant reduction in the risk
of death (HR: 0.64, P < 0.0001) was observed with sal-
vage chemotherapy (HR: 0.55 and 0.71 for CPT-11
and docetaxel, respectively).
The role of molecular targeted agents in second-line
therapy has gained interest. Recent trials reported that
ramucirumab monotherapy improved OS compared to
best supported care [18], and its combination with
weekly paclitaxel improved OS and PFS over weekly
paclitaxel alone [19]. Furthermore, a recent meta-analy-
sis of chemotherapy or targeted therapy [20] reported
that a beneﬁt of chemotherapy was found for patients
with good PS, while targeted agents showed some eﬃ-
cacy for patients with PS 1 or more, indicating that
symptomatic disease should not be immediately
excluded for further lines of therapy.
Recently, Higuchi et al. reported in their randomised
trial (n = 130), employing the same regimens as in this
trial, that biweekly CPT-11 plus CDDP signiﬁcantly
prolonged PFS (HR: 0.68) compared with CPT-11
alone, but that it did not demonstrate a survival beneﬁt
(HR: 1.00) in patients with metastatic or recurrent gas-
tric cancer that progressed after S-1-based ﬁrst-line
chemotherapy. In their study, approximately 30% and
60% of patients received S-1 monotherapy and com-
bination of S-1 and platinum-based therapy, respectively
[21]. Thus, taken together with the results of the present
study, the addition of platinum to CPT-11 as second-
line treatment may not have a survival beneﬁt, regard-
less of pretreatment with platinum.
Interestingly, our exploratory subgroup analysis
revealed that CPT-11/CDDP combination therapy was
signiﬁcantly more eﬀective for intestinal-type gastric
cancer than CPT-11 monotherapy, and similar results
are found in the literature, indicating that CPT-11/
CDDP combination therapy may be particularly eﬀec-
tive in intestinal-type as compared with diﬀuse-type gas-
tric cancer [4,22]. On the other hand, the eﬃcacies of the
regimens did not diﬀer between recurrent cases after S-1
adjuvant and advanced cases showing progression after
S-1 treatment, indicating that the disease status may not
aﬀect the treatment eﬀect.
Our trial has several limitations. The number of eligi-
ble patients was small and the prognoses of these
patients were better than expected. Therefore, a possibil-
ity of type two error cannot be denied. Further, applica-
tion of the present results may be limited, as
combination therapies containing platinum are cur-
rently the standard ﬁrst-line treatment. Lastly, with the
exception of histology type, we could not explore the
factors predictive of a beneﬁt of addition of platinum
to platinum-naı¨ve patients.
Table 3
Adverse events.
Any grade Grades 3–4
CPT-11 + CDDP (n = 82),
%
CPT-11 (n = 81),
%
P-
value
CPT-11 + CDDP (n = 82),
%
CPT-11 (n = 81),
%
P-
value
Leucopenia 85 64 0.002 11 12 0.785
Neutropenia 72 61 0.122 35 28 0.259
Anaemia 96 96 0.988 16 4 0.009
Thrombocytopenia 43 20 0.002 1 0 0.319
Nausea 48 53 0.481 4 5 0.687
Vomiting 24 25 0.964 1 4 0.305
Anorexia 59 56 0.701 6 9 0.534
Diarrhoea 26 46 0.007 0 3 0.152
Constipation 6 16 0.043 0 1 0.313
Fatigue 26 27 0.822 9 4 0.199
Mucositis 2 12 0.015 0 0 1.000
LDH 59 51 0.302 5 0 0.044
Creatinine 28 12 0.013 0 0 1.000
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In conclusion, our study did not show a signiﬁcant
diﬀerence in OS between CPT-11/CDDP combination
therapy and CPT-11 monotherapy in patients with pro-
gressive AGC previously treated with S-1 monotherapy.
However, in the subset analysis, we found that CPT-11/
CDDP combination therapy was associated with a bet-
ter OS in intestinal-type AGC.
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